Corporate Strategy

  • Continue the clinical development of intranasal administration of Foralumab for neurodegenerative disease indications:
    • Secondary Progressive, Multiple Sclerosis
    • Alzheimer's
    • Amyotrophic Lateral Sclerosis (ALS)
  • Advance to a Phase 1b clinical development trial of orally-administered Foralumab for the treatment of Crohn’s disease.
  • Submit an Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer's disease patients.
  • Submit an IND for Anti-IL-6R (TZLS-501) monoclonal antibodies.
  • Explore the combination of milciclib and gemcitabine in NSCLC subjects with pan KRAS-positive mutations.
  • Seek orphan drugs fast track or breakthrough designation for our product candidates where warranted.